Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 2018

View Archived Issues

Phase I safety data reported for cannabinoid therapy in drug-resistant pediatric epilepsy

Discovery of the oncological action of the long non-coding RNA, THOR, in renal cell carcinoma

Development of riluzole prodrugs for the treatment of amyotrophic lateral sclerosis

Biomarkers to identify candidates for CAR T-cell immunotherapy

Discovery of a novel enzymatic function of histone deacetylase 11

Tightening pores fights prostate cancer

Kidney cancer grows up, too

PIM-2 kinase suppresses T-cell responses to alloantigen and tumor cells

Cellect signs stem cell collaboration agreement with Cell2in

First patient treated in phase Ib study of resiniferatoxin for OA knee pain

VistaGen and Baylor College of Medicine collaborate on first-step study of AV-101

OrthoTrophix presents phase II results for TPX-100 in patients with knee osteoarthritis

FDA issues complete response letter regarding the sBLA for Eylea

Liverpool School of Tropical Medicine and collaborators patent compounds for filariasis

Mustang Bio, St. Jude's Children's Research Hospital to develop gene therapy for X-SCID

Council of Scientific and Industrial Research divulges caerulomycin A analogues

New Janus kinase inhibitors synthesized at Leo Pharma

REVOLUTION Medicines discovers SHP-2 inhibitors

Sunshine Lake Pharma presents acetyl-CoA carboxylase inhibitors

Illuminating the Black Box: Mechanism identified for thalidomide teratogenicity

Izana Bioscience begins phase II proof-of-concept study of namilumab in ankylosing spondylitis

Unum Therapeutics preparing phase I trial of ACTR T cells plus trastuzumab

Bayer, Haplogen to identify antiviral compounds for COPD exacerbations

The Leukemia & Lymphoma Society and Sutro Biopharma partner to develop STRO-001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...